FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2524035794> ?p ?o ?g. }

• W2524035794 endingPage "1214" @default.
• W2524035794 startingPage "1204" @default.
• W2524035794 abstract "BACKGROUND: Benign prostatic hyperplasia (BPH) is a common disease in men that is characterized by lower urinary tract symptoms. Pharmacologic treatment with alpha blockers (ABs) and 5-alpha reductase inhibitors (5ARIs) is recommended to alleviate symptoms, prevent disease progression that can lead to complications, and reduce health care costs. OBJECTIVE: To compare clinical, economic, and health care resource utilization outcomes among BPH patients treated with early continuous combination AB and 5ARI therapy (dutasteride vs. finasteride) using administrative claims data from the United States. METHODS: A retrospective analysis of administrative claims data from 2003-2013 was conducted to compare outcomes between patients with claims for early combination therapy with dutasteride + AB and patients with claims for early finasteride + AB. The study population included males aged older than 50 years with at least 1 medical claim with a diagnosis of BPH and pharmacy dispensing for AB and 5ARI therapies. Outcomes included acute urinary retention (AUR), prostate-related surgery, clinical progression, medical and pharmacy costs, and health care resource utilization. Inverse probability of treatment (IPT) weighted Cox proportional hazards, linear, and Poisson regression models were used to assess the association between outcomes and early combination therapy as appropriate. RESULTS: A total of 2,778 patients were included in the early finasteride + AB treatment cohort, and 4,125 patients were included in the early dutasteride + AB cohort. Dutasteride users were younger than finasteride users (mean age: 64.8 vs. 67.5 years, P < 0.001) and had a greater mean number of urologist visits (10.7 vs. 7.9, P < 0.001) during baseline. After adjusting for confounding using IPT weighting, no statistically significant difference was observed between dutasteride and finasteride for AUR (hazard ratio [HR] = 0.845, 95% CI = 0.660-1.070, P = 0.1643), prostate-related surgery (HR = 0.806, 95% CI = 0.568-1.171, P = 0.2525), and clinical progression (HR = 0.834, 95% CI = 0.663-1.043, P = 0.1122). While dutasteride was associated with higher pharmacy costs per month (adjusted monthly cost difference = $79, 95% CI = $45-$105), total all-cause medical costs were not significantly different between the 2 cohorts (adjusted monthly cost difference = -$44, 95% CI = -$110-$22). CONCLUSIONS: Clinical and economic outcomes were similar between the early dutasteride + AB and early finasteride + AB cohorts, with no statistically significant differences detected. DISCLOSURES: Funding for this study was provided by GlaxoSmithKline (HO-14-15325 and AVO110072). Bell and Swensen are employees of GlaxoSmithKline. DerSarkissian, Xiao, Duh, and Lefebvre are employed by Analysis Group, a consulting company that received research grants from GlaxoSmithKline to conduct this study. Study concept and design were contributed by Bell, Swensen, Lefebvre, and Duh. Bell and Duh acquired the data. DerSarkissian and Xiao performed the statistical analysis and interpreted the data along with Lefebvre, Duh, and Bell. DerSarkissian and Bell drafted the manuscript. All authors contributed equally to critically revising the manuscript and providing final approval of the submitted manuscript." @default.
• W2524035794 created "2016-10-07" @default.
• W2524035794 creator A5016377572 @default.
• W2524035794 creator A5019269759 @default.
• W2524035794 creator A5038717824 @default.
• W2524035794 creator A5049944206 @default.
• W2524035794 creator A5063896009 @default.
• W2524035794 creator A5077494238 @default.
• W2524035794 date "2016-10-01" @default.
• W2524035794 modified "2023-09-26" @default.
• W2524035794 title "Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States" @default.
• W2524035794 cites W1729580440 @default.
• W2524035794 cites W1925520630 @default.
• W2524035794 cites W1964370987 @default.
• W2524035794 cites W1964629962 @default.
• W2524035794 cites W1969786935 @default.
• W2524035794 cites W1974345369 @default.
• W2524035794 cites W1975219618 @default.
• W2524035794 cites W1979870734 @default.
• W2524035794 cites W2000445173 @default.
• W2524035794 cites W2006796265 @default.
• W2524035794 cites W2007002471 @default.
• W2524035794 cites W2009187570 @default.
• W2524035794 cites W2009604837 @default.
• W2524035794 cites W203858940 @default.
• W2524035794 cites W2038693293 @default.
• W2524035794 cites W2038881769 @default.
• W2524035794 cites W2053978887 @default.
• W2524035794 cites W2054957776 @default.
• W2524035794 cites W2058645699 @default.
• W2524035794 cites W2058677706 @default.
• W2524035794 cites W2061326496 @default.
• W2524035794 cites W2076846229 @default.
• W2524035794 cites W2081597080 @default.
• W2524035794 cites W2081679660 @default.
• W2524035794 cites W2105669626 @default.
• W2524035794 cites W2106355635 @default.
• W2524035794 cites W2113137108 @default.
• W2524035794 cites W2118811666 @default.
• W2524035794 cites W2121759271 @default.
• W2524035794 cites W2126104986 @default.
• W2524035794 cites W2136226351 @default.
• W2524035794 cites W2139636220 @default.
• W2524035794 cites W2146012618 @default.
• W2524035794 cites W2156670138 @default.
• W2524035794 cites W2184749154 @default.
• W2524035794 cites W2285202500 @default.
• W2524035794 cites W2409752089 @default.
• W2524035794 cites W2804551733 @default.
• W2524035794 cites W4236163484 @default.
• W2524035794 cites W65134806 @default.
• W2524035794 cites W73616958 @default.
• W2524035794 cites W2136174497 @default.
• W2524035794 doi "https://doi.org/10.18553/jmcp.2016.22.10.1204" @default.
• W2524035794 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27668569" @default.
• W2524035794 hasPublicationYear "2016" @default.
• W2524035794 type Work @default.
• W2524035794 sameAs 2524035794 @default.
• W2524035794 citedByCount "3" @default.
• W2524035794 countsByYear W25240357942017 @default.
• W2524035794 countsByYear W25240357942019 @default.
• W2524035794 countsByYear W25240357942023 @default.
• W2524035794 crossrefType "journal-article" @default.
• W2524035794 hasAuthorship W2524035794A5016377572 @default.
• W2524035794 hasAuthorship W2524035794A5019269759 @default.
• W2524035794 hasAuthorship W2524035794A5038717824 @default.
• W2524035794 hasAuthorship W2524035794A5049944206 @default.
• W2524035794 hasAuthorship W2524035794A5063896009 @default.
• W2524035794 hasAuthorship W2524035794A5077494238 @default.
• W2524035794 hasBestOaLocation W25240357941 @default.
• W2524035794 hasConcept C104863432 @default.
• W2524035794 hasConcept C121608353 @default.
• W2524035794 hasConcept C126322002 @default.
• W2524035794 hasConcept C126894567 @default.
• W2524035794 hasConcept C167135981 @default.
• W2524035794 hasConcept C2775874879 @default.
• W2524035794 hasConcept C2776235491 @default.
• W2524035794 hasConcept C2777562237 @default.
• W2524035794 hasConcept C2778878792 @default.
• W2524035794 hasConcept C2779478474 @default.
• W2524035794 hasConcept C2780435053 @default.
• W2524035794 hasConcept C2780542891 @default.
• W2524035794 hasConcept C2780546585 @default.
• W2524035794 hasConcept C2908647359 @default.
• W2524035794 hasConcept C2910366748 @default.
• W2524035794 hasConcept C29456083 @default.
• W2524035794 hasConcept C512399662 @default.
• W2524035794 hasConcept C71924100 @default.
• W2524035794 hasConcept C72563966 @default.
• W2524035794 hasConcept C99454951 @default.
• W2524035794 hasConceptScore W2524035794C104863432 @default.
• W2524035794 hasConceptScore W2524035794C121608353 @default.
• W2524035794 hasConceptScore W2524035794C126322002 @default.
• W2524035794 hasConceptScore W2524035794C126894567 @default.
• W2524035794 hasConceptScore W2524035794C167135981 @default.
• W2524035794 hasConceptScore W2524035794C2775874879 @default.
• W2524035794 hasConceptScore W2524035794C2776235491 @default.
• W2524035794 hasConceptScore W2524035794C2777562237 @default.

• next